These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 36233110)
1. Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping. Lee JY; Choi JW; Hwang S; Hahm SH; Ahn YH Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233110 [TBL] [Abstract][Full Text] [Related]
2. Investigation of Site-Specific Differences in Glycan Microheterogeneity by N-Glycopeptide Mapping of VEGFR-IgG Fusion Protein. Hahm YH; Lee JY; Ahn YH Molecules; 2019 Oct; 24(21):. PubMed ID: 31671706 [TBL] [Abstract][Full Text] [Related]
3. Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate. Shen Z; Wang Y; Xu H; Zhang Q; Sha C; Sun B; Li Q Int J Biol Macromol; 2021 Jun; 180():494-509. PubMed ID: 33684428 [TBL] [Abstract][Full Text] [Related]
4. Characterization of intact glycopeptides reveals the impact of culture media on site-specific glycosylation of EPO-Fc fusion protein generated by CHO-GS cells. Wang Q; Yang G; Wang T; Yang W; Betenbaugh MJ; Zhang H Biotechnol Bioeng; 2019 Sep; 116(9):2303-2315. PubMed ID: 31062865 [TBL] [Abstract][Full Text] [Related]
5. Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. Chandler KB; Pompach P; Goldman R; Edwards N J Proteome Res; 2013 Aug; 12(8):3652-66. PubMed ID: 23829323 [TBL] [Abstract][Full Text] [Related]
6. Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping. Bongers J; Devincentis J; Fu J; Huang P; Kirkley DH; Leister K; Liu P; Ludwig R; Rumney K; Tao L; Wu W; Russell RJ J Chromatogr A; 2011 Nov; 1218(45):8140-9. PubMed ID: 21978954 [TBL] [Abstract][Full Text] [Related]
7. N-glycan occupancy of Arabidopsis N-glycoproteins. Song W; Mentink RA; Henquet MG; Cordewener JH; van Dijk AD; Bosch D; America AH; van der Krol AR J Proteomics; 2013 Nov; 93():343-55. PubMed ID: 23994444 [TBL] [Abstract][Full Text] [Related]
11. Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM. Moh ES; Lin CH; Thaysen-Andersen M; Packer NH J Am Soc Mass Spectrom; 2016 Jul; 27(7):1143-55. PubMed ID: 27038031 [TBL] [Abstract][Full Text] [Related]
12. Quantitative structural characterization of local N-glycan microheterogeneity in therapeutic antibodies by energy-resolved oxonium ion monitoring. Toyama A; Nakagawa H; Matsuda K; Sato TA; Nakamura Y; Ueda K Anal Chem; 2012 Nov; 84(22):9655-62. PubMed ID: 23004563 [TBL] [Abstract][Full Text] [Related]
13. Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies. Kayili HM; Salih B J Proteomics; 2022 Sep; 267():104700. PubMed ID: 35995381 [TBL] [Abstract][Full Text] [Related]
14. Site-specific protein glycosylation analysis with glycan isomer differentiation. Hua S; Nwosu CC; Strum JS; Seipert RR; An HJ; Zivkovic AM; German JB; Lebrilla CB Anal Bioanal Chem; 2012 May; 403(5):1291-302. PubMed ID: 21647803 [TBL] [Abstract][Full Text] [Related]
15. Comparison of N-Glycopeptide to Released N-Glycan Abundances and the Influence of Glycopeptide Mass and Charge States on N-Linked Glycosylation of IgG Antibodies. Remoroza CA; Burke MC; Mak TD; Sheetlin SL; Mirokhin YA; Cooper BT; Goecker ZC; Lowenthal MS; Yang X; Wang G; Tchekhovskoi DV; Stein SE J Proteome Res; 2024 Apr; 23(4):1443-1457. PubMed ID: 38450643 [TBL] [Abstract][Full Text] [Related]
16. Efficient Expression of Functionally Active Aflibercept with Designed N-glycans. Keshvari T; Melnik S; Sun L; Niazi A; Aram F; Moghadam A; Kogelmann B; Wozniak-Knopp G; Kallolimath S; Ramezani A; Steinkellner H Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38651409 [TBL] [Abstract][Full Text] [Related]
17. Generation of site-distinct N-glycan variants for in vitro bioactivity testing. Brühlmann D; Vuillemin T; Satwekar A; Galano E; Palmese A; D'Angelo A; Manco Z; Souquet J; Broly H; Sauer M; Hemberger J; Jordan M Biotechnol Bioeng; 2019 May; 116(5):1017-1028. PubMed ID: 30659587 [TBL] [Abstract][Full Text] [Related]
18. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept. Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222 [TBL] [Abstract][Full Text] [Related]
19. Efficient HCD-pd-EThcD approach for N-glycan mapping of therapeutic antibodies at intact glycopeptide level. Li M; Zhu W; Zheng H; Zhang J Anal Chim Acta; 2022 Jan; 1189():339232. PubMed ID: 34815030 [TBL] [Abstract][Full Text] [Related]
20. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry. Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]